(Q37127287)

English

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

fatty liver disease

0 references

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

object named as

Toshifumi Hibi

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

object named as

Takumi Hirata

1

1 reference

ORCID Public Data File 2021

author name string

Kengo Tomita

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Toshihide Kawai

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hirokazu Yokoyama

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Akira Shimada

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Masahiro Kikuchi

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hiroshi Hirose

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hirotoshi Ebinuma

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Junichiro Irie

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Keisuke Ojiro

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yoichi Oikawa

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hidetsugu Saito

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Hiroshi Itoh

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

13 August 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

International journal of endocrinology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

587140

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Nonalcoholic fatty liver disease and vascular risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Structural basis for telmisartan-mediated partial activation of PPAR gamma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

The epidemiology of nonalcoholic fatty liver disease: a global perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

GI epidemiology: nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Therapeutic potential of angiotensin II receptor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

14 September 2017

Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

27 June 2018

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

27 June 2018

Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3755443

3 September 2018

Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/23997767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Noninvasive in vivo quantitative assessment of fat content in human liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/23997767

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2013/587140

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37127287&oldid=2119441083"